Drug Profile
Research programme: calcitonin gene related peptide analogues - VasoGenix Pharmaceuticals
Alternative Names: CGRP analogues - VasoGenixLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator VasoGenix Pharmaceuticals
- Developer Novelion Therapeutics; VasoGenix Pharmaceuticals
- Class Neuropeptides
- Mechanism of Action Calcitonin gene-related peptide agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute heart failure; Heart failure
- Discontinued Ischaemic heart disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-heart-failure in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA (SC, Controlled release)
- 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics